Picture of Zydus Lifesciences logo

ZYDUSLIFE — Zydus Lifesciences News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Zydus to launch generic semaglutide injections in India after patent expiry in March

Fixes formatting in the last bullet

Feb 25 - Zydus Lifesciences ZYDU.NS will launch generic versions of semaglutide injections for obesity and diabetes in India after patent expiry of the Ozempic active ingredient in late March, it said on Wednesday.

Zydus plans to launch the drug under three brand names -  SEMAGLYN, MASHEMA, ALTERME.

Unlike existing treatments that require multiple single-use pens, Zydus' single adjustable pen will let patients select different doses, lowering costs, it says.

Zydus holds exclusive rights to its reusable pen with prefilled cartridges.

Patent protection for semaglutide expires in India late in March 2026, triggering a rush among Indian drugmakers to prepare lower-cost versions.

Semaglutide is the active ingredient in Danish drugmaker Novo Nordisk's NOVOb.CO blockbuster diabetes drug Ozempic and weight-loss drug Wegovy.

In January, Zydus received approval from India's regulator to make and sell generic versions of the weight-loss drugs.

Larger peer Dr Reddy's Laboratories REDY.NS is likely to launch its generic semaglutide injection in the country in March under the brand name Obeda, Reuters reported earlier on Wednesday, citing two people familiar with the matter.

 (Reporting by Nishit Navin in Bengaluru; Editing by Sahal Muhammed)

Recent news on Zydus Lifesciences

See all news